What is the clinical evidence from this study?

Study design: Other. Population: Fulminant myocarditis. Intervention: Prolonged Impella support (PROPELLA concept). Primary outcome: Cardiac immune cell presence and integrin expression.

What does this research mean for the field?

Prolonged Impella support (the PROPELLA concept) in fulminant myocarditis decreases cardiac immune cell presence and integrin expression during left ventricular unloading, potentially providing disease-altering effects beyond mechanical circulatory support. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to explore how the PROPELLA concept can improve outcomes in patients with fulminant myocarditis through unloading the heart and reducing inflammation.

June 21, 2026Open Access

Mode-of-action of the PROPELLA concept in fulminant myocarditis

Key Result

Prolonged Impella support (PROPELLA concept) in fulminant myocarditis decreased cardiac immune cell presence and integrin expression during left ventricular unloading.

Key Points

The aim is to explore how the PROPELLA concept can improve outcomes in patients with fulminant myocarditis through unloading the heart and reducing inflammation.
Investigated the effect of Impella support on cardiac remodelling and inflammatory responses.
Measured changes in immune cell presence and integrin expression during unloading.
Focused on the role of mechano-transduction pathways in inflammation.
Prolonged Impella support significantly decreased the presence of cardiac immune cells.
Expression of integrins α1, α5, α6, α10, and β6 reduced during the unloading process.
Insights suggest that Impella support offers additional benefits beyond mechanical support.

Structured PICO

Does prolonged Impella support (PROPELLA concept) alter cardiac immune cell presence and integrin expression in fulminant myocarditis?

Population

Patients with chronic fulminant myocarditis

Intervention

Prolonged Impella support (PROPELLA concept)

Outcome

Cardiac immune cell presence and integrin α1, α5, α6, α10 and β6 expressionsurrogate

Prolonged Impella support in fulminant myocarditis may provide disease-altering effects by reducing cardiac inflammation and integrin expression, potentially enhancing myocardial recovery.

Abstract

AIMS: Haemodynamic load induces cardiac remodelling via mechano-transduction pathways, which can further trigger inflammatory responses. We hypothesized that particularly in an inflammatory disorder such as myocarditis, a therapeutic strategy is required which, in addition to providing adequate circulatory support, unloads the left ventricle, decreases cardiac wall stress, and mitigates inflammatory responses. METHODS AND RESULTS: Axial flow pumps such as the Impella systems comply with these requirements. Here, we report a potential mode-of-action of prolonged Impella support (PROPELLA concept) in fulminant myocarditis, including a decrease in cardiac immune cell presence, and integrin α1, α5, α6, α10 and β6 expression during unloading. CONCLUSION: PROPELLA may provide benefits beyond its primary function of mechanical circulatory support in the form of additional disease-altering effects, which may contribute to enhanced myocardial recovery/remission in patients with chronic fulminant myocarditis.

Expert Takes1 quote

“Like with ECMO, the Impella device also provides circulatory support, but the heart is unloaded. The Impella, which is implanted in the left ventricle, acts like a propeller in a boat. It swaps the blood out, so the heart does not have to pump. This reduces the volume load, and therefore reduces the stress for the heart.”

Carsten Tschöpe, Cardiologist, Charité Hospital, BerlinCharité Hospitalauto_pipelineView source